Company Overview and News

to your dashboard

Headline News

Sangamo's Powerful Pipeline Drives Significant Upside

2017-11-17 seekingalpha
While there has been a high level of excitement over the past few years with regard to CRISPR gene editing possibilities, some of the previously leading methods for effective genome manipulation and gene therapy have been lost in the mix. Sangamo Therapeutics (SGMO) has a strong proprietary product in their Zinc Finger Nuclease [ZFN] technology for genome modulation. They have recently generated significant buzz surrounding their widely successful quarter, and have laid a strong foundation moving forward. (52-0)

CRISPR Therapeutics Earnings Update: Maintains The Lead In Cas9 Clinical Trials

2017-11-10 seekingalpha
CRSP's update on their pipeline is encouraging - IND on track for 2017, first company in the CRISPR-Cas9 clinical space. (25-0)

Calyxt Jumping Into A Crowded Space

2017-10-31 seekingalpha
Calyxt is using the excitement regarding cutting edge technologies in the genome editing space to support its product pipeline. (49-0)

Vertex Pharmaceuticals (VRTX) Q3 2017 Results - Earnings Call Transcript

2017-10-26 seekingalpha
Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our Third Quarter 2017 Financial Results Conference Call. Participants are now in a listen-only mode. And later, we will open the lines for question. This call is recorded. A replay will be available later tonight on our website. (11-0)

Big Biotech In The CRISPR Game: Novartis And Vertex Lead The Pack

2017-10-23 seekingalpha
CRISPR Therapeutics and Intellia Therapeutics are partnered with the strongest large biotech plays in the space in Vertex and Novartis respectively. (310-1)

The Alliance for Regenerative Medicine Announces Election of 2018 ARM Executive Committee and Board of Directors

2017-10-04 marketwired
WASHINGTON, DC--(Marketwired - Oct 4, 2017) - The Alliance for Regenerative Medicine (ARM), announced today the election of its 2018 Executive Committee and Board of Directors. (39-2)

Avoid Unintended Stock Market Bets By Understanding Benchmarks

2017-10-03 seekingalpha
In a recent Financial Planning article, Craig Israelsen advocated using stock market size segments to construct portfolios rather than a total market approach. His conclusion may be perfectly valid for market participants willing and able to bear greater small-stock exposure, but his analysis fails to adequately take account of this source of risk. He compared returns of several index funds and reviewed results of combining them in a couple of different ways. (10-0)

Founding CRISPR CEO to Step Down for Personal Reasons, New Leader Named

2017-10-02 biospace
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, announced today that Dr. Samarth Kulkarni, Ph.D., currently President of CRISPR Therapeutics, Inc., has been promoted to the role of Chief Executive Officer. Dr. Kulkarni will assume the role effective December 1, 2017. (12-0)

Gene Editing Could Modify And Cure Disease: CRISPR Vs. TALENs

2017-09-21 seekingalpha
During the past decade, technology breakthroughs enabling the modification of complex genomes have changed the primary goal of research in biotechnology and synthetic biology: now research is focused not on “treatment” of diseases but on its modification and cure. The ability to directly edit living cells has brought gene therapy and precision medicine into a new era, one that will accelerate the pace of scientific research and increase the value of molecular diagnostic tests. (25-1)

CRISPR Field Patent Fight Extended: Focus On Science, Time Frames, Risks

2017-09-21 seekingalpha
CRISPR Therapeutics is currently under appreciated considering they are the closest company to beginning clinical trials. (101-2)

Versant Venture Capital IV, L.P. discloses 6.78% ownership in CRSP / CRISPR Therapeutics AG -

September 15, 2017 - Versant Venture Capital IV, L.P. has filed an SC 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,752,256 shares of CRISPR Therapeutics AG (NASDAQ:CRSP). This represents 6.78 percent ownership of the company.

This Technology Could Make You Rich -- and Change the World As We Know It

2017-08-13 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. (0-3)

MilliporeSigma to Be Granted European Patent for CRISPR Technology

2017-08-07 genengnews
The European Patent Office (EPO) has told MilliporeSigma it intends to grant approval of its patent application covering the company's CRISPR technology used in a genomic integration method for eukaryotic cells—the second key patent awarded in Europe covering the gene-editing technology.

Behind The Hype, Crispr Is A Story Of Slow Progress And Acrimony

2017-08-03 seekingalpha
Some people reading this morning's mainstream press headlines about a Nature paper describing the correction of a germline mutation using Crispr (NASDAQ:CRSP) might be excused for thinking that we are entering a Gattaca-like world of designer babies.

BRIEF-Crispr Therapeutics says Dr. Tony W. Ho to head R&D

2017-08-01 reuters
* Crispr Therapeutics appoints Dr. Tony W. Ho to head research & development Source text for Eikon: Further company coverage:

CUSIP: H17182108